Summary
In a significant market movement during July 2025, Ultromics was the subject of a vc funding. The transaction achieved a gross valuation of £41,559,933. Leading the round was GV, Allegis Capital, Oxford Science Enterprises, University of Chicago Medicine, L&G Capital, Blue Venture Fund, UPMC Enterprises, Oxford University, Lightrock.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
GV
Lead Investor / Acquirer
Allegis Capital
Lead Investor / Acquirer
Oxford Science Enterprises
Lead Investor / Acquirer
University of Chicago Medicine
Lead Investor / Acquirer
L&G Capital
Lead Investor / Acquirer
Blue Venture Fund
Lead Investor / Acquirer
UPMC Enterprises
Lead Investor / Acquirer
Oxford University
Lead Investor / Acquirer
Lightrock
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series C prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in